about
Mass treatment with azithromycin for trachoma: when is one round enough? Results from the PRET Trial in the GambiaAssociation between ocular bacterial carriage and follicular trachoma following mass azithromycin distribution in The GambiaNon-participation during azithromycin mass treatment for trachoma in The Gambia: heterogeneity and risk factorsCosts of testing for ocular Chlamydia trachomatis infection compared to mass drug administration for trachoma in the Gambia: application of results from the PRET studyCross-Sectional Surveys of the Prevalence of Follicular Trachoma and Trichiasis in The Gambia: Has Elimination Been Reached?When can antibiotic treatments for trachoma be discontinued? Graduating communities in three African countriesActive trachoma and ocular Chlamydia trachomatis infection in two Gambian regions: on course for elimination by 2020?Mass treatment with azithromycin for trachoma control: participation clusters in households.Trachoma prevalence and associated risk factors in the gambia and Tanzania: baseline results of a cluster randomised controlled trial.Design and baseline data of a randomized trial to evaluate coverage and frequency of mass treatment with azithromycin: the Partnership for Rapid Elimination of Trachoma (PRET) in Tanzania and The Gambia.Risk factors for active trachoma and ocular Chlamydia trachomatis infection in treatment-naïve trachoma-hyperendemic communities of the Bijagós Archipelago, Guinea Bissau.Incremental cost of conducting population-based prevalence surveys for a neglected tropical disease: the example of trachoma in 8 national programsMapping the global distribution of trachoma: why an updated atlas is needed.Diagnostic accuracy of a prototype point-of-care test for ocular Chlamydia trachomatis under field conditions in The Gambia and Senegal.Mass administration of azithromycin and Streptococcus pneumoniae carriage: cross-sectional surveys in the Gambia.A diagnostics platform for the integrated mapping, monitoring, and surveillance of neglected tropical diseases: rationale and target product profiles.Anthropometric indices of Gambian children after one or three annual rounds of mass drug administration with azithromycin for trachoma control.Conjunctival scarring in trachoma is associated with the HLA-C ligand of KIR and is exacerbated by heterozygosity at KIR2DL2/KIR2DL3.Prevalence of Chlamydia trachomatis infection among low- and high-risk Filipino women and performance of Chlamydia rapid tests in resource-limited settings.Short-term increase in prevalence of nasopharyngeal carriage of macrolide-resistant Staphylococcus aureus following mass drug administration with azithromycin for trachoma control.Accurate detection of Neisseria gonorrhoeae ciprofloxacin susceptibility directly from genital and extragenital clinical samples: towards genotype-guided antimicrobial therapy.The eClinical Care Pathway Framework: a novel structure for creation of online complex clinical care pathways and its application in the management of sexually transmitted infections.Epidemiology and control of trachoma: systematic review.Population-based prevalence survey of follicular trachoma and trachomatous trichiasis in the Casamance region of Senegal.Spatial clustering of high load ocular Chlamydia trachomatis infection in trachoma: a cross-sectional population-based study.Impact of deploying multiple point-of-care tests with a 'sample first' approach on a sexual health clinical care pathway. A service evaluation.Effect of azithromycin mass drug administration for trachoma on spleen rates in Gambian children.The impact of community level treatment and preventative interventions on trachoma prevalence in rural Ethiopia.Risk factors for active trachoma and Chlamydia trachomatis infection in rural Ethiopia after mass treatment with azithromycin.Self-sampling and self-testing for STIs and HIV: the case for consistent nomenclature.Using the eSexual Health Clinic to access chlamydia treatment and care via the internet: a qualitative interview study.Two doses of azithromycin to eliminate trachoma in a Tanzanian community.The impact of a single round of community mass treatment with azithromycin on disease severity and ocular Chlamydia trachomatis load in treatment-naïve trachoma-endemic island communities in West Africa.Detection of Chlamydia trachomatis in rectal specimens in women and its association with anal intercourse: a systematic review and meta-analysis.The eSexual Health Clinic system for management, prevention, and control of sexually transmitted infections: exploratory studies in people testing for Chlamydia trachomatis.'Test n Treat (TnT)'- Rapid testing and same-day, on-site treatment to reduce rates of chlamydia in sexually active further education college students: study protocol for a cluster randomised feasibility trial.Health-related quality of life and psychosocial impacts of a diagnosis of non-specific genital infection in symptomatic heterosexual men attending UK sexual health clinics: a feasibility study."Test n Treat" (TnT): a cluster randomised feasibility trial of on-site rapid Chlamydia trachomatis tests and treatment in ethnically diverse, sexually active teenagers attending technical collegesCan remote STI/HIV testing and Clinical Care be compatible with robust public health surveillance?Modelling-based evaluation of the costs, benefits and cost-effectiveness of multipathogen point-of-care tests for sexually transmitted infections in symptomatic genitourinary medicine clinic attendees
P50
Q28533873-D99FE94D-231E-4D49-A2D6-38F156649A7CQ28534860-3BB885F0-CB98-4A3F-AAF3-111358BBEABCQ28542612-87013AE3-22C1-41F8-812F-C83609FE44C2Q28546645-F82EEDF2-F5C6-46B1-AEFF-97111DCBFF4BQ28554221-D5625E82-20AC-4884-9BB1-C2A84F7FCB78Q33468389-DF950AF1-DE81-4178-A6E2-41A5312A174CQ33520204-E33B1CCD-BEE5-4C8E-8F75-4E12BA1B1AEFQ33722084-5E12DC1B-45A7-4A26-B9C1-9955F52DEA88Q33745187-3A8722CD-9376-4665-BAE1-C2168ADC13AFQ33806236-DBAB89E3-A7BF-4DC1-AE77-45E68B1F09D2Q33812010-1F896F58-9401-4EB4-917C-D9C77479701CQ33847464-EF4B4E67-D186-4BD8-97F7-0A68582DEB35Q33955445-56CD2E0D-FE0A-4A66-BD80-13D43F3EE0F9Q33988876-09F3AD8E-2341-4F48-8512-6499F55BCF1CQ34002736-AAB630AB-244F-47F0-BCF9-21140A43D17CQ34364970-5607A94D-99E9-462C-8DF7-1FCBAAFCE4D2Q34611086-C29946DC-74D4-45B0-A953-96B4D4EA54C2Q35126671-0131243E-30D7-4FD6-924D-DEDBABFE08C5Q36314501-5EBA75D9-F527-4848-8FFF-E7BD0A3E9540Q36325816-47313488-F06C-4ADB-B96C-AE669CC8C203Q36684164-D91BC714-C9AD-4E25-A549-889F2A75E187Q37119369-781DB5D7-4ACE-4683-AC28-C60337360FE1Q37165258-5E232F8F-8B62-4F6B-9265-C53A3693E31BQ37833738-8002CE65-3EB7-4631-957A-8AF1932EDB9DQ37834293-79A5D5E9-E3B0-4214-B502-9C546BEEA9D1Q37835010-CD275403-D855-4663-BC7B-7C21EB1289E7Q37845126-3D868E46-3234-431A-A885-5A16321733F4Q37857807-341000A4-BD40-4D3D-87F8-DA5273324987Q37858036-3459526D-B9F9-4296-80B9-9EBBC272E8F8Q40464784-C5152462-4F1F-4356-808E-1D74BADD0E57Q41990003-39148318-42DD-4401-B05C-69571F0FDA38Q43415711-0C9335F4-2BB2-424A-A394-97E40CE143F1Q47103856-3A7645DF-D47E-4D8A-9C2A-E77A86C6B528Q50069317-650EDE4A-A87F-4B1E-8D82-F0791EC8603AQ52409475-24D88C50-0013-4227-A52E-9E9EC0AFAACBQ55291001-94A0D764-52EF-470D-B7C5-9E850B3EA048Q55632017-09919951-749E-4A50-83E0-D9783CF62810Q58582895-1E881F96-7D1B-4CFB-8CA3-442ADEFC4F79Q58642962-CB2C7796-9711-44B1-9C66-D2FED8927C4AQ58753889-73A001FC-1EFC-495C-93D5-564631414DF2
P50
description
hulumtuese
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Emma M Harding-Esch
@ast
Emma M Harding-Esch
@en
Emma M Harding-Esch
@es
Emma M Harding-Esch
@nl
type
label
Emma M Harding-Esch
@ast
Emma M Harding-Esch
@en
Emma M Harding-Esch
@es
Emma M Harding-Esch
@nl
prefLabel
Emma M Harding-Esch
@ast
Emma M Harding-Esch
@en
Emma M Harding-Esch
@es
Emma M Harding-Esch
@nl
P108
P106
P108
P21
P31
P496
0000-0002-1432-8109